Tarlatamab's role in SCLC
Prof Charles Rudin speaks to ecancer about the extended follow-up results from the phase III DeLLphi-304 trial, which evaluated tarlatamab, a DLL3-targeting bispecific T-cell engager immunotherapy, compared with chemotherapy in patients with small cell lung cancer (SCLC) whose disease had progressed after first-line platinum-based chemotherapy.
After a median follow-up of 23 months, tarlatamab continued to demonstrate a significant overall survival benefit, reducing the risk of death by 38%.
Median overall survival was 13.6 months with tarlatamab compared with 8.4 months with chemotherapy.
Dr Rudin says that the benefit was maintained in high-risk subgroups, including patients with platinum-resistant disease and those with brain metastases.
Tarlatamab also improved progression-free survival, with median progression-free survival of 4.2 months versus 3.2 months, and demonstrated more durable disease control.
Treatment discontinuations due to treatment-related adverse events were also lower with tarlatamab (3% vs 7%), and no new safety signals emerged with extended follow-up.
These findings reinforce the durable survival benefit and manageable safety profile of tarlatamab as a treatment option for patients with previously treated SCLC, including those with high-risk disease.
Tarlatamab's role in SCLC
Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC
Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer